Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo

Completed · Not applicable · Has a placebo group

Conditions studied: Bronchiectasis, Pulmonary Disease, Chronic Obstructive

In brief

The rationale of this study is to conduct a summative (i.e., validation) usability test of Ciprofloxacin Dry Powder for Inhalation (DPI) and the associated Instructions for Use.

Key facts

Study ID

NCT02661438

Run by

Bayer

People needed

46

Starts

2016-01-12

Expected to finish

2016-03-17

Last updated by the study team

2018-12-19

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects (male and female) with non-cystic fibrosis bronchiectasis (NCFB) or chronic obstructive pulmonary disease (COPD)
• Subjects must be aged ≥40
• Subject must be able to independently manage and administer their NCFB/COPD medications

You may not qualify if…

• Subjects with recent exacerbation
• Subjects with recent significant hemoptysis in the four weeks before screening (and/or during the screening period)
• Subjects allergic to quinine
• Known chronic bronchial asthma

Where it is running

• Study site — Vero Beach, Florida, United States
• Study site — Jamaica, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.